Aquatic Capital Management LLC Lowers Stake in Guardant Health, Inc. (NASDAQ:GH)

Aquatic Capital Management LLC lessened its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 20.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 164,842 shares of the company's stock after selling 42,358 shares during the period. Aquatic Capital Management LLC owned 0.13% of Guardant Health worth $5,036,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock valued at $368,205,000 after buying an additional 350,606 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Guardant Health by 19.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after purchasing an additional 238,037 shares during the last quarter. Nikko Asset Management Americas Inc. raised its holdings in Guardant Health by 15.6% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after acquiring an additional 197,729 shares during the period. Norges Bank purchased a new stake in Guardant Health during the 4th quarter worth about $36,438,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Guardant Health by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,016,533 shares of the company's stock worth $31,055,000 after acquiring an additional 13,395 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Scotiabank upped their target price on shares of Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Monday, February 24th. Stifel Nicolaus raised their price target on Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday. Piper Sandler raised their price objective on Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Guggenheim reiterated a "buy" rating and issued a $56.00 target price on shares of Guardant Health in a research note on Monday, February 24th. Finally, The Goldman Sachs Group lifted their price objective on Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Twenty-one investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $51.64.

Guardant Health Stock Performance

Shares of NASDAQ:GH traded down $1.75 on Friday, reaching $47.12. The company's stock had a trading volume of 2,903,400 shares, compared to its average volume of 2,175,840. The company has a 50-day simple moving average of $43.61 and a 200 day simple moving average of $37.94. The company has a market cap of $5.82 billion, a P/E ratio of -13.25 and a beta of 1.45. Guardant Health, Inc. has a 52-week low of $17.99 and a 52-week high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.08. The company had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm's revenue for the quarter was up 20.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.46) earnings per share. On average, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.